Moderna, Inc. — Director's Dealing 2024

May 7, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2024-05-03

Reporting Person: Berenson Stephen (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-03	Common Stock	M	732	—	Acquired	22203	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-03	Restricted Stock Units	$	M	732	Disposed		Common Stock (732)	Direct
2024-05-06	Stock Option (Right to Buy)	$122.13	A	7557	Acquired	2034-05-06	Common Stock (7557)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The shares subject to this restricted stock unit award vested in full on May 3, 2024.

F3: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.